Suitable Monitoring Approaches to Antiretroviral Therapy in Resource-Poor Settings: Setting the Research Agenda

Kent, David M.; McGrath, Donnie; Loannidis, John P. A.; Bennish, Michael L.
July 2003
Clinical Infectious Diseases;7/1/2003 Supplement 1, Vol. 37, pS13
Academic Journal
The delivery of antiretroviral therapy in the developing world requires guidelines for the appropriate monitoring of therapy, including monitoring for treatment effectiveness and treatment failure, drug toxicities, adherence to therapy, and the emergence of resistant organisms. Guidelines developed in wealthy industrialized countries, which rely heavily on laboratory tests often unavailable in the developing world, may not be feasible or appropriate for resource-limited settings. Even if the standard of care routinely delivered in industrialized settings cannot be replicated, antiretroviral treatment programs with less-intense monitoring have the potential to reduce morbidity and mortality from human immunode-ficiency virus. Research to identify monitoring strategies that provide the greatest benefit to those living with human immunodeficiency virus in resource-limited settings and that use the available technologies and resources needs to be conducted within a conceptual and ethical framework that takes into account differences between rich and poor countries.


Related Articles

  • Simple, Effective Interventions Are Key to Improving Adherence in Marginalized Populations. Mills, Edward J.; Cooper, Curtis // Clinical Infectious Diseases;10/1/2007, Vol. 45 Issue 7, p916 

    The article presents the authors' view on the article "Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: A marginal structural model analysis," by M.L. Petersen and colleagues. The association between pillbox use and both improved...

  • HIV-1 gp41 as a Target for Viral Entry Inhibition. Root, Michael J.; Steger, H. Kirby // Current Pharmaceutical Design;Jun2004, Vol. 10 Issue 15, p1805 

    The recent success of the fusion inhibitor T-20 (enfuvirtide) in clinical studies has ushered in a new chapter in the development of anti-HIV-1 therapeutics. T-20 is the first FDA-approved drug that targets the viral transmembrane protein gp41. This protein, along with gp120, promotes viral...

  • Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents. Christopher, M. E.; Wong, J. P. // Current Pharmaceutical Design;Jun2006, Vol. 12 Issue 16, p1995 

    Rapid advances in viral genomics, gene function and regulation, as well as in rational drug design, have led to the development of gene-based drugs that can induce protective antiviral immunity, interfere with viral replication, suppress viral gene expression or cleave viral mRNAs. Several such...

  • Prevalence and determinants of nonadherence to highly active antiretroviral therapy among people living with HIV/AIDS in Ibadan, Nigeria. Olowookere, Samuel A.; Fatiregun, Akinola A.; Akinyemi, Joshua O.; Bamgboye, Afolabi E.; Osagbemi, Gordon K. // Journal of Infection in Developing Countries;2008, Vol. 2 Issue 5, p369 

    Objective: To determine the level of nonadherence to highly active antiretroviral therapy (HAART) and to explore the association of factors militating against adherence and nonadherence to therapy among people living with HIV/AIDS (PLWHA) at an Antiretroviral Clinic in Ibadan, Nigeria. Design: A...

  • Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy. Robertson, Jaime; Meier, Matthew; Wall, Jennifer; Jun Ying; Fichtenbaum, Carl J. // Clinical Infectious Diseases;6/1/2006, Vol. 42 Issue 11, p1639 

    Background. Clinical deterioration after initiation of antiretroviral therapy may result from restored immunity. There is no standard clinical definition for immune reconstitution syndrome. The objectives of this study were to validate a proposed definition and to identify factors predictive of...

  • A life-long antiretroviral treatment of congenital HIV disease, associated with a mixed fat redistribution syndrome and osteopenia already occurred during pre-pubertal age. Manfredi, Roberto; Calza, Leonardo; Chiodo, Francesco // International Journal of STD & AIDS;Jul2002, Vol. 13 Issue 7, p504 

    An extraordinarily rare case report of mixed fat redistribution syndrome associated with osteopenia but not with relevant metabolic abnormalities is documented in a prepubertal child with congenital HIV infection treated with antiretroviral therapy since the age of six months, up to the present...

  • Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. Gulick, Roy M.; Zhaohui Su; Flexner, Charles; Hughes, Michael D.; Skolnik, Paul R.; Wilkin, Timothy J.; Gross, Robert; Krambrink, Amy; Coakley, Eoin; Greaves, Wayne L.; Zolopa, Andrew; Reichman, Richard; Godfrey, Catherine; Hirsch, Martin; Kuritzkes, Daniel R. // Journal of Infectious Diseases;7/15/2007, Vol. 196 Issue 2, p304 

    Background. Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study. Methods. The present study was a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficiency virus (HIV)-infected subjects...

  • Long-Term Effects of Highly Active Antiretroviral Therapy in Pretreated, Vertically HIV Type 1-Infected Children: 6 Years of Follow-Up. Resino, Salvador; Resino, Rosa; Micheloud, Dariela; Gutiérrez, Dolores Gurbindo; Léon, Juan Antonio; Ramos, José Tomás; Ciria, Luis; de José, Isabel; Mellado, José; Muñoz-Fernández, Ángeles // Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, p862 

    Background. Several studies of children with human immunodeficiency virus (HIV) type 1 infection have demonstrated sustained increases in CD4+ cell count, even when virological failure has occurred after receipt of highly active antiretroviral therapy (HAART), but these studies were of limited...

  • Identification of Authentic Inhibitors of HIV-1 Integration. Witvrouw, M.; Fikkert, V.; Vercammen, J.; Van Maele, B.; Engelborghs, Y.; Debyser, Z. // Current Medicinal Chemistry - Anti-Infective Agents;Apr2005, Vol. 4 Issue 2, p153 

    Current strategies for the treatment of human immunodeficiency virus (HIV) infection are based on cocktails of drugs that target the viral entry step and the enzymes reverse transcriptase or protease. At present, the clinical benefit of this combination therapy for HIV-infected patients is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics